全球血栓药物市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

全球血栓药物市场需求预计将从 2023 年的 313.7 亿美元增至 2032 年的近 589 亿美元，2024-2032 年研究期间复合CAGR为 7.25%。

血栓药物是用于预防或治疗血栓形成（血栓）的药物。这些药物，包括抗凝血剂和抗血小板剂，对于治疗深部静脉栓塞和肺栓塞等疾病以及预防某些心血管疾病患者的中风至关重要。

市场动态

血栓药物市场的驱动因素包括血栓性疾病盛行率的增加、人口老化以及肥胖和久坐行为等与生活方式相关的危险因子。血栓药物，包括抗凝血剂和抗血小板剂，对于预防和治疗深部静脉栓塞、肺栓塞和中风等疾病至关重要。心血管疾病盛行率的上升以及外科和医疗环境中有效血栓预防的需求促进了市场的成长。此外，药物配方的进步和安全性提高的新型抗凝血剂的开发刺激了市场需求。人们对血栓形成危险因子的认识不断增强以及早期介入的重要性进一步推动了市场的发展。对血栓管理的监管支持和直接口服抗凝血剂（DOAC）的引入有助于血栓药物治疗的持续发展。此外，正在进行的以个人化医疗和标靶治疗为重点的研发活动旨在提高血栓药物的疗效和安全性，从而塑造市场轨迹。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球血栓药物市场的各个细分市场进行了包容性评估。血栓药物产业的成长和趋势为本研究提供了整体方法。

市场区隔

血栓药物市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助战略家确定相应产品或服务的目标人群以及即将到来的机会。

按药物类别

• Xa 因子抑制剂
• 低分子肝素
• P2Y12 血小板抑制剂
• 其他的

按指示

• 肺栓塞
• 心房震颤
• 深层静脉栓塞
• 其他的

按配销通路

• 医院药房
• 零售药局
• 网路药局

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲血栓药物市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。血栓药物市场的主要参与者包括葛兰素史克公司、百特国际公司、强生公司、赛诺菲公司、百时美施贵宝公司、阿斯利康公司、拜耳公司、阿斯彭製药控股有限公司、勃林格殷格翰公司、辉瑞公司。对竞争格局的整体看法，包括各种策略发展，例如关键併购、未来能力、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

• 报告说明
  • 客观的
  • 目标受众
  • 独特的销售主张 (USP) 和产品
• 研究范围
• 研究方法论
  • 市场研究过程
  • 市场研究方法论

第 2 章：执行摘要

• 市集亮点
• 全球市场概况

第 3 章：血栓药物 - 产业分析

• 简介 - 市场动态
• 市场驱动因素
• 市场限制
• 机会
• 产业动态
• 波特五力分析
• 市场吸引力分析
  • 按药品类别分類的市场吸引力分析
  • 按指标进行的市场吸引力分析
  • 按配销通路分類的市场吸引力分析
  • 市场吸引力分析：按地区

第 4 章：价值链分析

• 价值链分析
• 原料分析
  • 原料清单
  • 原料厂商清单
  • 主要原物料价格走势
• 潜在买家名单
• 行销管道
  • 直效行销
  • 间接行销
  • 行销通路发展趋势

第 5 章：全球血栓药物市场分析：依药物类别

• 按药物类别概述
• 历史和预测数据
• 按药物类别分析
• Xa 因子抑制剂
• 低分子肝素
• P2Y12 血小板抑制剂
• 其他的

第 6 章：全球血栓药物市场分析：依适应症分类

• 按适应症概述
• 历史和预测数据
• 按指标分析
• 肺栓塞
• 心房震颤
• 深层静脉栓塞
• 其他的

第 7 章：全球血栓药物市场分析：按分销管道

• 按配销通路分類的概览
• 历史和预测数据
• 按配销通路分析
• 医院药房
• 零售药局
• 网路药局

第 8 章：全球血栓药物市场分析：依地理位置

• 区域展望
• 介绍
• 北美销售分析
  • 概览、历史与预测资料销售分析
  • 北美按细分市场销售分析
  • 北美按国家销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概览、历史与预测资料销售分析
  • 欧洲按细分市场销售分析
  • 欧洲按国家销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 义大利销售分析
  • 俄罗斯销售分析
  • 欧洲其他地区销售分析
• 亚太地区销售分析
  • 概览、历史与预测资料销售分析
  • 亚太地区按细分市场销售分析
  • 亚太地区国家/地区销售分析
  • 中国销售分析
  • 印度销售分析
  • 日本销售分析
  • 韩国销售分析
  • 澳洲销售分析
  • 东南亚销售分析
  • 亚太地区其他地区销售分析
• 拉丁美洲销售分析
  • 概览、历史与预测资料销售分析
  • 拉丁美洲按细分市场销售分析
  • 拉丁美洲按国家销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利销售分析
  • 拉丁美洲其他地区销售分析
• 中东和非洲销售分析
  • 概览、历史与预测资料销售分析
  • 中东和非洲按细分市场销售分析
  • 中东和非洲国家销售分析
  • 沙乌地阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 中东其他地区和非洲销售分析

第 9 章：血栓药物公司的竞争格局

• 血栓药物市场竞争
• 伙伴关係/协作/协议
• 併购
• 新产品发布
• 其他发展

第 10 章：公司简介

• 公司股份分析
• 市场集中度
• GSK plc
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Baxter International Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Johnson & Johnson
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Sanofi
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Bristol-Myers Squibb Company
• 公司简介
• 公司收入
• 产品
• 最近的发展
• AstraZeneca plc
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Bayer AG
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Aspen Pharmacare Holdings Limited
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Boehringer Ingelheim GmbH Pfizer Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

The global demand for Thrombosis Drugs Market is presumed to reach the market size of nearly USD 58.9 BN by 2032 from USD 31.37 BN in 2023 with a CAGR of 7.25% under the study period 2024 - 2032.

Thrombosis drugs are medications used to prevent or treat thrombosis, which is the formation of blood clots. These drugs, including anticoagulants and antiplatelet agents, are essential in managing conditions like deep vein thrombosis and pulmonary embolism and preventing stroke in patients with certain cardiovascular diseases.

MARKET DYNAMICS

The thrombosis drugs market is driven by factors such as the increasing prevalence of thrombotic disorders, aging populations, and lifestyle-related risk factors such as obesity and sedentary behavior. Thrombosis drugs, including anticoagulants and antiplatelet agents, are essential in preventing and treating conditions like deep vein thrombosis, pulmonary embolism, and stroke. The rising prevalence of cardiovascular diseases and the need for effective thromboprophylaxis in surgical and medical settings contribute to market growth. Additionally, advancements in drug formulations and the development of novel anticoagulants with improved safety profiles stimulate market demand. The expanding awareness of thrombosis risk factors and the importance of early intervention further fuel the market. Regulatory support for thrombosis management and the introduction of direct oral anticoagulants (DOACs) contribute to the evolving landscape of thrombosis drug therapies. Moreover, ongoing research and development activities focused on personalized medicine and targeted therapies aim to enhance the efficacy and safety of thrombosis drugs, shaping the market's trajectory.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of thrombosis drugs. The growth and trends of thrombosis drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the thrombosis drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

• Factor Xa Inhibitor
• Low Molecular Weight Heparin
• P2Y12 Platelet Inhibitor
• Others

By Indication

• Pulmonary Embolism
• Atrial Fibrillation
• Deep Vein Thrombosis
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Thrombosis Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Thrombosis Drugs market include GSK plc, Baxter International Inc., Johnson & Johnson, Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, Bayer AG, Aspen Pharmacare Holdings Limited, Boehringer Ingelheim GmbH Pfizer, Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . THROMBOSIS DRUGS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug Class
  • 3.7.2 Market Attractiveness Analysis By Indication
  • 3.7.3 Market Attractiveness Analysis By Distribution Channel
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL THROMBOSIS DRUGS MARKET ANALYSIS BY DRUG CLASS

• 5.1 Overview by Drug Class
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Drug Class
• 5.4 Factor Xa Inhibitor Historic and Forecast Sales by Regions
• 5.5 Low Molecular Weight Heparin Historic and Forecast Sales by Regions
• 5.6 P2Y12 Platelet Inhibitor Historic and Forecast Sales by Regions
• 5.7 Others Historic and Forecast Sales by Regions

6 . GLOBAL THROMBOSIS DRUGS MARKET ANALYSIS BY INDICATION

• 6.1 Overview by Indication
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Indication
• 6.4 Pulmonary Embolism Historic and Forecast Sales by Regions
• 6.5 Atrial Fibrillation Historic and Forecast Sales by Regions
• 6.6 Deep Vein Thrombosis Historic and Forecast Sales by Regions
• 6.7 Others Historic and Forecast Sales by Regions

7 . GLOBAL THROMBOSIS DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 7.1 Overview by Distribution Channel
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Distribution Channel
• 7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
• 7.5 Retail Pharmacies Historic and Forecast Sales by Regions
• 7.6 Online Pharmacies Historic and Forecast Sales by Regions

8 . GLOBAL THROMBOSIS DRUGS MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2. North America By Segment Sales Analysis
  • 8.3.3. North America By Country Sales Analysis
  • 8.3.4. United State Sales Analysis
  • 8.3.5. Canada Sales Analysis
  • 8.3.6. Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2. Europe by Segment Sales Analysis
  • 8.4.3. Europe by Country Sales Analysis
  • 8.4.4. United Kingdom Sales Analysis
  • 8.4.5. France Sales Analysis
  • 8.4.6. Germany Sales Analysis
  • 8.4.7. Italy Sales Analysis
  • 8.4.8. Russia Sales Analysis
  • 8.4.9. Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2. Asia Pacific by Segment Sales Analysis
  • 8.5.3. Asia Pacific by Country Sales Analysis
  • 8.5.4. China Sales Analysis
  • 8.5.5. India Sales Analysis
  • 8.5.6. Japan Sales Analysis
  • 8.5.7. South Korea Sales Analysis
  • 8.5.8. Australia Sales Analysis
  • 8.5.9. South East Asia Sales Analysis
  • 8.5.10. Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2. Latin America by Segment Sales Analysis
  • 8.6.3. Latin America by Country Sales Analysis
  • 8.6.4. Brazil Sales Analysis
  • 8.6.5. Argentina Sales Analysis
  • 8.6.6. Peru Sales Analysis
  • 8.6.7. Chile Sales Analysis
  • 8.6.8. Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2. Middle East & Africa by Segment Sales Analysis
  • 8.7.3. Middle East & Africa by Country Sales Analysis
  • 8.7.4. Saudi Arabia Sales Analysis
  • 8.7.5. UAE Sales Analysis
  • 8.7.6. Israel Sales Analysis
  • 8.7.7. South Africa Sales Analysis
  • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE THROMBOSIS DRUGS COMPANIES

• 9.1. Thrombosis Drugs Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10 . COMPANY PROFILES OF THROMBOSIS DRUGS INDUSTRY

• 10.1. Company Share Analysis
• 10.2. Market Concentration Rate
• 10.3. GSK plc
  • 10.3.1. Company Overview
  • 10.3.2. Company Revenue
  • 10.3.3. Products
  • 10.3.4. Recent Developments
• 10.4. Baxter International Inc.
  • 10.4.1. Company Overview
  • 10.4.2. Company Revenue
  • 10.4.3. Products
  • 10.4.4. Recent Developments
• 10.5. Johnson & Johnson
  • 10.5.1. Company Overview
  • 10.5.2. Company Revenue
  • 10.5.3. Products
  • 10.5.4. Recent Developments
• 10.6. Sanofi
  • 10.6.1. Company Overview
  • 10.6.2. Company Revenue
  • 10.6.3. Products
  • 10.6.4. Recent Developments
• 10.7. Bristol-Myers Squibb Company
  • 10.7.1. Company Overview
  • 10.7.2. Company Revenue
  • 10.7.3. Products
  • 10.7.4. Recent Developments
• 10.8. AstraZeneca plc
  • 10.8.1. Company Overview
  • 10.8.2. Company Revenue
  • 10.8.3. Products
  • 10.8.4. Recent Developments
• 10.9. Bayer AG
  • 10.9.1. Company Overview
  • 10.9.2. Company Revenue
  • 10.9.3. Products
  • 10.9.4. Recent Developments
• 10.10. Aspen Pharmacare Holdings Limited
  • 10.10.1. Company Overview
  • 10.10.2. Company Revenue
  • 10.10.3. Products
  • 10.10.4. Recent Developments
• 10.11. Boehringer Ingelheim GmbH Pfizer Inc.
  • 10.11.1. Company Overview
  • 10.11.2. Company Revenue
  • 10.11.3. Products
  • 10.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Drug Class (USD MN)
• Factor Xa Inhibitor Market Sales by Geography (USD MN)
• Low Molecular Weight Heparin Market Sales by Geography (USD MN)
• P2Y12 Platelet Inhibitor Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Analysis Market by Indication (USD MN)
• Pulmonary Embolism Market Sales by Geography (USD MN)
• Atrial Fibrillation Market Sales by Geography (USD MN)
• Deep Vein Thrombosis Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Analysis by Distribution Channel (USD MN)
• Hospital Pharmacies Market Sales by Geography (USD MN)
• Retail Pharmacies Market Sales by Geography (USD MN)
• Online Pharmacies Market Sales by Geography (USD MN)
• Global Thrombosis Drugs Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Thrombosis Drugs Report
• Market Research Process
• Market Research Methodology
• Global Thrombosis Drugs Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Drug Class
• Market Attractiveness Analysis by Indication
• Market Attractiveness Analysis by Distribution Channel
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Drug Class (USD MN)
• Factor Xa Inhibitor Market Sales by Geography (USD MN)
• Low Molecular Weight Heparin Market Sales by Geography (USD MN)
• P2Y12 Platelet Inhibitor Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Analysis by Indication (USD MN)
• Pulmonary Embolism Market Sales by Geography (USD MN)
• Atrial Fibrillation Market Sales by Geography (USD MN)
• Deep Vein Thrombosis Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Analysis by Distribution Channel (USD MN)
• Hospital Pharmacies Market Sales by Geography (USD MN)
• Retail Pharmacies Market Sales by Geography (USD MN)
• Online Pharmacies Market Sales by Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.